CECarolann L. Espy

Carolann L. Espy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carolann L. Espy has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Jacob Samuel Brenner

    Department of Systems Pharmacology and Translational Therapeutics Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

    3 shared publications
  • Aparajeeta Majumder

    Department of Systems Pharmacology and Translational Therapeutics Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

    2 shared publications
  • David B. Frank

    Division of Cardiology, Department of Pediatrics, University of Pennsylvania, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    2 shared publications
  • Elizabeth D. Hood

    Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine

    2 shared publications
  • Eno-Obong Essien

    Division of Pulmonary Allergy, and Critical Care, Department of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

    2 shared publications
  • Fengyi Dong

    Department of Bioengineering University of Pennsylvania Philadelphia Pennsylvania USA

    2 shared publications

Latest Publications

  • Open Access

    Localized NF‐κB Inhibition Reduces Lipid Nanoparticle‐Associated Inflammation

    by Carolann L. Espy, Jichuan Wu, Serena Omo‐Lamai, Liuqian Wang, Fengyi Dong, Aleksa Milosavljevic, Sarah O'NEill, Taylor Brysgel, Yufei Wang, Michael Zaleski, et al.

    Lipid nanoparticles (LNPs) are widely used for nucleic acid delivery, yet their clinical utility is limited by an acute inflammatory response post‐administration. LNP‐associated inflammation (LAI) manifests as de novo inflammation in select organs (e.g., in the lungs after inhalation) and severely worsens pre‐existing inflammation. NF‐κB is a key transcription factor mediating this inflammation and represents a promising target for LAI mitigation strategies. However, systemic NF‐κB inhibition carries risks of global immunosuppression, highlighting the need for localized inhibition. Here, we screen a panel of direct and indirect small molecule inhibitors of NF‐κB for their ability to reduce LAI without disrupting LNPs’ expression. We identify inhibitors that load efficiently into LNPs, retain anti‐inflammatory activity in vitro and in vivo, and preserve expression of cargo mRNA in target tissues. Our results demonstrate that co‐formulation of NF‐κB inhibitors with cargo nucleic acids enables localized immunomodulation in LNPs, offering a modular strategy to enhance the safety profile of LNPs for therapeutic use in inflammatory or high‐risk patient populations.


  • Open Access

    Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity

    by Nicolas Marzolini, Taylor V. Brysgel, Ryan J. Rahman, Eno‐Obong Essien, Saw Y. Nwe, Jichuan Wu, Aparajeeta Majumder, Manthan N. Patel, Sachchidanand Tiwari, Carolann L. Espy, et al.

    DNA‐lipid nanoparticles (DNA‐LNPs) loaded with inhibitors of the cGAS‐STING pathway enable safe and effective delivery of DNA in vivo. Herein, we report the first instances of extrahepatic DNA‐LNP targeting. DNA‐LNPs conjugated to antibodies against PECAM‐1 or VCAM‐1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM‐targeted transgene expression increases over two weeks, resulting in markedly higher lung‐to‐liver expression ratios than our previous PECAM‐targeted mRNA‐LNPs. Off‐target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half‐life. We further improve this expression specificity by replacing full‐length antibodies with Fab fragments. Single‐cell analysis reveals a key mechanism underlying the improvements in organ‐specificity: target organ expression is dominated by long‐lived endothelial cells, while off‐target liver delivery and expression are in non‐endothelial cells with shorter half‐lives. Collectively, these studies demonstrate that targeted DNA‐LNPs achieve high levels of organ‐ and cell‐type‐specific transgene expression and thus provide a therapeutic platform for dozens of endothelial‐centric diseases.


  • Open Access

    Targeting DNA-LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity

    by Nicolas Marzolini, Taylor V. Brysgel, Eno-Obong Essien, Ryan J. Rahman, Jichuan Wu, Aparajeeta Majumder, Manthan N. Patel, Sachchidanand Tiwari, Carolann L. Espy, Vladimir V. Shuvaev, et al.

    DNA-lipid nanoparticles (DNA-LNPs) loaded with inhibitors of the cGAS-STING pathway enable safe and effective delivery of DNA in vivo . Herein, we report the first instances of extrahepatic DNA-LNP targeting. DNA-LNPs conjugated to antibodies against PECAM-1 or VCAM-1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM-targeted transgene expression increases over two weeks, resulting in markedly higher lung-to-liver expression ratios than our previous PECAM-targeted mRNA-LNPs. Off-target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half-life. We further improve this expression specificity by replacing full-length antibodies with Fab fragments. Single-cell analysis reveals a key mechanism underlying the improvements in organ-specificity: target organ expression is dominated by long-lived endothelial cells, while off-target liver delivery and expression are in non-endothelial cells with shorter half-lives. Collectively, these studies demonstrate that targeted DNA-LNPs achieve high levels of organ- and cell-type-specific transgene expression and thus provide a therapeutic platform for dozens of endothelial-centric diseases.